10 / 11
What patients expect from clinical trials
The final major discussion examined clinical trials from the patient perspective, including the particular challenges of research involving children and young people.
Clinical trials offer the possibility of contributing to knowledge and, sometimes, accessing a promising intervention. They also involve uncertainty, travel, time away from work or school, repeated imaging and blood tests, complex consent documents, unknown side effects and the possibility of receiving placebo. Participation is never a simple act of hope; it is a significant commitment by patients and families.
Access itself is unequal. A trial may be available only in selected countries or large expert centres. Travel may take hours and create costs that are not always fully reimbursed. Strict eligibility criteria can exclude people who are highly motivated to participate. These obstacles become even greater for patients in large countries, underserved regions and lower-income settings.
The group called for clearer, age-appropriate information and consent materials that explain not only the scientific purpose of a study but also what participation will mean in daily life.
Patient involvement in protocol development was seen as essential. Patients can identify burdens that may be invisible to researchers, from the acceptability of MRI schedules to the impact of appointments on school, employment and family responsibilities.
Participants questioned whether traditional endpoints fully capture what matters. Total kidney volume and eGFR are important, but they do not describe pain, fatigue, anxiety, the ability to work or study, or the effect of treatment on daily life. Patient-reported outcomes and quality-of-life measures must be included from the beginning, not added as an afterthought.
Paediatric research presents additional scientific problems. Children may begin with normal or near-normal kidney function, making changes in eGFR difficult to detect within a conventional trial period. Height-adjusted total kidney volume also has limitations in growing children.
Developing meaningful, acceptable endpoints for early disease will require collaboration between paediatric nephrologists, trial methodologists, regulators, patients and families.
The reasons people stop study medication or leave a trial must also be understood. Side effects, disease progression, practical burden and disappointment may all play a role. Participants distinguished between stopping the investigational treatment and withdrawing completely from follow-up. When a participant can no longer take the study drug but is willing to continue attending assessments, the resulting information can be extremely valuable.
At the same time, the right to withdraw without giving a reason must be protected. Follow-up questions should never become pressure or coercion. Carefully designed exit questionnaires and patient-led evaluation at the end of a study may help researchers learn what worked and what should change, while respecting individual choice.
Several participants asked what happens when a trial ends. Families may have invested years in a study and then lose access to a treatment that appeared beneficial while regulatory and reimbursement processes continue. Open-label extension studies, compassionate-use or early-access programmes and clear post-trial access plans were proposed as important considerations, particularly in paediatric research but also for adults.
Long-term follow-up is equally important. A trial endpoint may be reached after one or two years, but benefits or adverse effects may emerge much later. Continuing to collect data—and supporting clinicians and centres to do so—can help answer questions that the original trial period could not.
Patient organisations also considered their own responsibilities. They can raise awareness of clinical research, help people find appropriate trials and explain questions to ask, but should not persuade individuals to enter a particular study. The decision belongs to the patient and family, supported by independent information and their healthcare team.